| Biologic Agent | %LDAS | Source | |
|---|---|---|---|
| Abatacept after IR to anti-TNF therapy | Induction -Month 12 | 18.3% | ATTAIN + LTE study (Genovese 2007) |
| Maintenance | |||
| Month 18 | 24.2% | ATTAIN + LTE study (Genovese 2007) | |
| Month 24 | 28% | ATTAIN + LTE study (Genovese 2007) | |
| Anti-TNF agents | Induction - Month 18 | 11% | REACT trial (Bombardieri 2007) |
| Maintenance - Month 24 | 21.5% | ATTAIN reanalysis afterIR to 2 anti-TNF agents | |
| Rituximab after IR to anti-TNF therapy | Induction -Month 12 | 18.3% | REFLEX + LTE study (Keystone 2007) |
| Maintenance | |||
| Month 18 | 24.2% | REFLEX + LTE study (Keystone 2007) | |
| Month 24 | 28% | Keystone (EULAR 2007) | |
| DMARDS | Month 24 | 5% | Clinical experts opinion |